Isoniazid | Vibepedia
Isoniazid, also known as isonicotinic acid hydrazide, is a first-line antibiotic used for the treatment of tuberculosis, often in combination with other…
Contents
Overview
Isoniazid was first synthesized in 1912 by Nikolai Nikolayevich Zelinsky, a Russian chemist, but its anti-tuberculosis activity was not discovered until the 1940s. The discovery of its therapeutic properties is attributed to Gerhard Domagk, a German scientist who was awarded the Nobel Prize in Physiology or Medicine in 1939. Isoniazid is now used in combination with other medications, such as Rifampicin and Pyrazinamide, to treat active tuberculosis, and is also effective against atypical types of mycobacteria, such as M. avium and M. kansasii.
💡 How It Works
Isoniazid is a prodrug that, when activated by catalase-peroxidase KatG, generates adducts and radicals that inhibit the formation of the mycobacterial cell wall. This mechanism of action is similar to that of other antibiotics, such as Ethambutol, which also target the mycobacterial cell wall. However, isoniazid is more effective against certain strains of tuberculosis, such as M. tuberculosis, and is often used as a first-line treatment. The development of isoniazid resistance is a major concern, and is often caused by mutations in the ahpC, inhA, kasA, and katG genes of M. tuberculosis.
🌎 Cultural Impact
Isoniazid has had a significant cultural impact, particularly in the treatment of tuberculosis, which was once a major public health concern. The development of isoniazid and other antibiotics has led to a significant decline in tuberculosis-related deaths, and has improved the quality of life for millions of people worldwide. However, the rise of antibiotic resistance, including isoniazid resistance, is a major concern, and has led to increased efforts to develop new antibiotics and improve treatment strategies. Organizations such as the World Health Organization and the Centers for Disease Control and Prevention are working to combat antibiotic resistance and improve tuberculosis treatment outcomes.
🔬 Legacy & Future
The legacy of isoniazid is complex, with both positive and negative aspects. On the one hand, isoniazid has been a crucial tool in the fight against tuberculosis, and has saved millions of lives. On the other hand, the development of isoniazid resistance has led to significant challenges in tuberculosis treatment, and has highlighted the need for new antibiotics and improved treatment strategies. The future of isoniazid and other antibiotics will depend on the development of new technologies and strategies to combat antibiotic resistance, and on the continued efforts of scientists, clinicians, and public health officials to improve tuberculosis treatment outcomes. Researchers at institutions such as the National Institutes of Health and the University of California, Los Angeles are working to develop new antibiotics and improve our understanding of antibiotic resistance.
Key Facts
- Year
- 1912
- Origin
- Russia
- Category
- science
- Type
- concept
Frequently Asked Questions
What is isoniazid used for?
Isoniazid is used to treat tuberculosis, particularly in combination with other medications like Rifampicin and Pyrazinamide. It is also effective against atypical types of mycobacteria, such as M. avium and M. kansasii.
How does isoniazid work?
Isoniazid is a prodrug that, when activated by catalase-peroxidase KatG, generates adducts and radicals that inhibit the formation of the mycobacterial cell wall. This mechanism of action is similar to that of other antibiotics, such as Ethambutol.
What are the side effects of isoniazid?
Is isoniazid still used today?
Yes, isoniazid is still widely used today, particularly in combination with other medications, to treat tuberculosis. However, the development of isoniazid resistance is a major concern, and has led to increased efforts to develop new antibiotics and improve treatment strategies.
What is the future of isoniazid?
The future of isoniazid will depend on the development of new technologies and strategies to combat antibiotic resistance, and on the continued efforts of scientists, clinicians, and public health officials to improve tuberculosis treatment outcomes. Researchers at institutions such as the National Institutes of Health and the University of California, Los Angeles are working to develop new antibiotics and improve our understanding of antibiotic resistance.